Multiple myeloma trials in South Korea
36 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Busan, Daegu, Hwasun-gun, Incheon, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236EU 2023-509208-14-00Registry updated 2026-08-24
Phase 3RecruitingTrial-stage medicine
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Seoul
- Age
- 18 years and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575EU 2023-507871-23-00Registry updated 2026-08-24
Phase 1/2RecruitingTrial-stage medicine
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Seoul
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839EU 2022-501941-63-00Registry updated 2026-08-19
Phase 1/2RecruitingTrial-stage medicine
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Seoul
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780EU 2023-507809-34-00Registry updated 2026-08-18
Phase 3RecruitingTrial-stage medicine
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Seoul
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978Registry updated 2026-08-14
Phase 3RecruitingTrial-stage medicine
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Hwasun, Jeonju, Seoul, Ulsan
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101EU 2024-516030-35-00Registry updated 2026-04-22
Phase 1/2RecruitingTrial-stage medicine
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Hwasun, Seoul
- Age
- 12 years and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555Registry updated 2026-03-24
No phaseNot yet recruitingResearch participation
Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study
- Where
- Seongnam-si
- Age
- 19 years to 80 years
- People
- 20
- Run by
- Seoul National University Bundang Hospital
See details and how to joinNCT07305662Registry updated 2026-01-21
Phase 1/2RecruitingTrial-stage medicine
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
- Where
- Hwasun, Seoul
- Age
- 19 years and over
- People
- 75 worldwide
- Run by
- YOUNGIL KOH
See details and how to joinNCT06645678Registry updated 2025-12-03
Phase 2RecruitingTrial-stage medicine
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
- Where
- Seoul
- Age
- 19 years and over
- People
- 40
- Run by
- Seoul National University Hospital
See details and how to joinNCT06920251Registry updated 2025-12-03
No phaseRecruitingResearch participation
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
- Where
- Seocho
- Age
- 19 years and over
- People
- 174
- Run by
- Sung-Soo Park
See details and how to joinNCT07051850Registry updated 2025-07-15
All Multiple myeloma trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.